Asian high yield outlook Thoughts on investing in Asian high yield bonds

Ross Dilkes, portfolio manager for UBS-AM's Asian high yield strategy gave three pointers on investing in Asian high yield bonds during the COVID-19 outbreak.

23 Jun 2020

We caught up with Ross Dilkes, portfolio manager for UBS Asset Management’s Asian high yield strategy to hear his thoughts on how he is investing in the asset class during the COVID-19 outbreak.

He brought up three pointers for Asian high yield investors to bear in mind:


Asian high yield outlook 1. Income in not everything; quality counts too

Many investors look to Asian high yield for its strong income potential. As rates in most of the developed world are dropping to zero (or close), the appeal of the asset class has become stronger.

While Asian credit with yields in the higher end of the spectrum may look tempting Ross cautions against blindly investing in them just for the sake of chasing the highest yields.

Income is not everything in high yield investing. Bond prices fluctuate and investors need look at total returns. This means taking holistic view of returns and accounting for adverse credit events, said Ross.

To get a gauge on this, Ross relies on the meticulous company research done by our credit analysts in the Asian fixed income team. Research helps to identify some of the higher yielding credits with weak fundamentals; this could be due to the poor industry outlook which they operate in or companies with weak balance sheets or strategic positioning.
While prices of these higher yielding credits may hold up well during non-crisis periods, they are likely to be rattled badly when there is market stress. "And very often, the high income received may not be enough to compensate for the loss if bond prices fall,” Ross added.

Our preference has been to hold better quality names within the Asian high yield space.

As we have seen in the COVID-19 outbreak, high yield names, regardless of their ratings, have sold off indiscriminately across the board. This was caused by investors who required liquidity and sold off higher quality assets first as there were no takers for those in the lower end of the rating spectrum (which have already been performing badly).

As the COVID-19 outbreak eventually stabilizes, the better rated high yield credits will be the first to recover as their operations are more robust, their balance sheets more resilient and they have more diverse financing channels available. As for the lower rated ones, we expect their price recovery at a much later point when the higher rated assets have fully priced in the potential return expectations.

In Asian high yield bonds, we had estimated 2020 default to be around 3% at the start of the year. Given the different circumstances, we have now revised this to 5-6%. At this level, investors in Asian high yield are still well compensated for those risks.

Now’s the time for Asian high yield bonds

"We expect to see a normalization in yields over the next 1 -2 years and that will create a very compelling opportunity … from a return perspective"

Ross Dilkes
Portfolio Manager
Asian high yield bonds


Asian high yield outlook 2. Stay active, be nimble, think dynamically

Ross spoke about how the focus on total return drives the way he and the team manage and position the UBS Asian high yield strategy. “We look at total returns and not just headline yield because we want to limit downside risks for investors. To be successful, we need to be nimble in allocating capital and position in where we see value,” said Ross.

Cash as liquidity buffer and ‘risk lever’

While the COVID-19 outbreak was still a China-centric issue at the start of this year, Ross started building up cash in anticipation as he thought that markets were not pricing in the risk of a possible slow-down there. As the outbreak spread globally, this cautious move was useful as “we were not forced to sell any securities for cash”. This has helped the strategy to successfully steer through some very volatile days.

In addition to serving as a liquidity buffer, the increased cash in the UBS Asian high yield portfolio also acts as a “risk lever”.

Holding cash gives us the ammunition to buy back into relatively cheaper credits as we spot opportunities.

said Ross.

Ross also manages duration actively. At the start of 2020, the portfolio was structurally overweight in duration as the team have been expecting further rate cuts. With the Federal Reserve (FED) cutting their policy rate now close to zero, the duration position was reduced to neutral (vs the benchmark).

Another example where Ross has put capital to work swiftly is in Asia currencies. With poor sentiment and falling tourist arrivals, Asian currencies have generally not fared well. So he has been proactively looking to short some Asian currencies against the US Dollar and Japanese Yen. This has been a complementary driver of returns, supporting the implementation of our strategic views.
Currency positions are a small part of the overall portfolio and are only used tactically when opportunities arise.


Asian high yield outlook 3. China is important but don’t forget India and Indonesia

China is a major issuer in the Asian high yield universe and has a market share of more than 50%. And China real estate companies have been tapping the offshore market to raise funds for its projects. At the moment, China real estate is about 38% of the Asian high yield market.

Chinese property high yield issuers can be mis-understood by investors. And that’s again where the due-diligence of our analysts come in.

Ross explained that the structural dynamics in China makes the investment case for Chinese high yield real estate companies compelling. “A lot of the what’s driving demand is urbanization and the growing middle class. These trends will continue to stay as China progresses.”

With the COVID-19 outbreak now stabilized in China, the on the ground channel checks have shown that activities are picking up in property sales offices and construction sites.

 China, India and Indonesia are major high yield markets in Asia

However, not all China high yield real estate issuers are worth investing in, Ross cautioned. The UBS Asian high yield strategy is invested in large, leading property developers. These companies have more diverse funding options and that is useful today where liquidity is scare. Over the years, they have also accumulated the experience in dealing with severe market cycles eg in 2011 and 2014.
And there are risks to our outlook, especially if the government decides to control house prices. However, housing is a key store of wealth for Chinese and very important to China’s economy. That’s why Ross and team believe the government will maintain a fine balance between controlling speculation and promoting growth.

But the UBS-AM team looks actively outside of China too. India and Indonesia are two other important markets in the Asian high yield space. The India high yield market has been stressed and this sort of environment is really useful in differentiating our investment process. There are many businesses there with scale and strong management. We find opportunities that fit our investment criteria and that is why we built up positions in selected sectors in India like alternative energy.

The UBS Asian high yield solution has a sustained track record of successful active investing

Ready for Asian high yield bonds?

Get acquainted now with the UBS-AM Asian high yield portfolio

Subscribe now

Perspectives matter. Tune in to our insights.

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2020 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.